James Sinka - Boston & SF(@jamessinka):Daraxonrasib ~doubles the survival rate of patients with metastatic pancreatic cancer. 13.2 months for patients taking daraxonrasib versus 6.7 months for those on standard chemotherapy. These results are stellar, standing ovation is due.

James Sinka - Boston & SF

@jamessinka

Founder @reactorfieldai - helping scientists & deep tech startups use AI like frontier labs. AI changed SWE, science is next. Unicorn Founder Chemist (YCW19)

参加 July 2016

2.1K フォロー中 3.3K ファン

James Sinka - Boston & SF@jamessinka

2026.06.01 04:20

Daraxonrasib ~doubles the survival rate of patients with metastatic pancreatic cancer. 13.2 months for patients taking daraxonrasib versus 6.7 months for those on standard chemotherapy. These results are stellar, standing ovation is due.